메뉴 건너뛰기
Journal of the American Academy of Dermatology
Volumn 53, Issue 4, 2005, Pages 692-693
Side effects of the biologics

(1)  Heymann, Warren R a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

BIOLOGICAL PRODUCT; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;
EID: 25844479251     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2005.06.004     Document Type: Article
Times cited : (5)
References (9)
  • 1
    • 4544347621 scopus 로고    scopus 로고
    • Considerations with the use of biological therapy in the treatment of rheumatoid arthritis
    • R.M. Fleischmann, I. Iqbal, and R.L. Stern Considerations with the use of biological therapy in the treatment of rheumatoid arthritis Expert Opin Drug Saf 3 2004 391 403
    • (2004) Expert Opin Drug Saf , vol.3 , pp. 391-403
    • Fleischmann, R.M.1    Iqbal, I.2    Stern, R.L.3
  • 3
    • 0242660438 scopus 로고    scopus 로고
    • Lymphoma rates are low but increased in patients with psoriasis: Results from a population-based cohort study in the United Kingdom
    • J.M. Gelfand, J. Berlin, A. VanVoorhees, and D.J. Margolis Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom Arch Dermatol 139 2003 1425 1429
    • (2003) Arch Dermatol , vol.139 , pp. 1425-1429
    • Gelfand, J.M.1    Berlin, J.2    Vanvoorhees, A.3    Margolis, D.J.4
  • 4
    • 0036900501 scopus 로고    scopus 로고
    • Tumor necrosis factor antagonist therapy and lymphoma development: Twenty-six cases reported to the Food and Drug Administration
    • S.L. Brown, M.H. Greene, S.K. Gershon, E.T. Edwards, and M.M. Braun Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration Arthritis Rheum 46 2002 3151 3158
    • (2002) Arthritis Rheum , vol.46 , pp. 3151-3158
    • Brown, S.L.1    Greene, M.H.2    Gershon, S.K.3    Edwards, E.T.4    Braun, M.M.5
  • 5
    • 25844505174 scopus 로고    scopus 로고
    • Food and Drug Administration Arthritis Advisory Committee March 4
    • Food and Drug Administration Arthritis Advisory Committee March 4, 2003. Available at: www.fda.gov/ohrms/dockets/ac/03/briefing/3930b1.htm. Accessed on May 30, 2005.
    • (2003)
  • 6
    • 17644374819 scopus 로고    scopus 로고
    • Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas
    • P. Geborek, A. Bladström, C. Turesson, A. Gulfe, I.F. Petersson, and T. Saxne Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas Ann Rheum Dis 64 2005 699 703
    • (2005) Ann Rheum Dis , vol.64 , pp. 699-703
    • Geborek, P.1    Bladström, A.2    Turesson, C.3    Gulfe, A.4    Petersson, I.F.5    Saxne, T.6
  • 8
    • 4644281717 scopus 로고    scopus 로고
    • Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas
    • A.M. Tsimberidou, F.J. Giles, M. Duvic, and R. Kurzrock Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas J Am Acad Dermatol 51 2004 200 204
    • (2004) J Am Acad Dermatol , vol.51 , pp. 200-204
    • Tsimberidou, A.M.1    Giles, F.J.2    Duvic, M.3    Kurzrock, R.4
  • 9
    • 2642539404 scopus 로고    scopus 로고
    • Anti-tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer
    • D.P. Symmons, and A.J. Silman Anti-tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: no clear answer Arthritis Rheum 50 2004 1703 1706
    • (2004) Arthritis Rheum , vol.50 , pp. 1703-1706
    • Symmons, D.P.1    Silman, A.J.2

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.